OM1 Contributes to Alzheimer’s Disease Research With New PremiOM Dataset of Over 1 Million Patients

The depth of data derived from the new dataset will contribute to early disease intervention and research to improve patient outcomes and quality of life

BOSTON--(BUSINESS WIRE)--OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical data, registries, and globally recognized thought leadership today announced the new release of its Alzheimer’s disease PremiOM dataset. OM1 combines multiple real-world data sources – including specialists’ electronic medical records (EMR), medical and pharmacy claims, social determinants of health (SDoH), and mental health assessments – with medical language processing and advanced AI capabilities to generate deep clinical insights for patients with Alzheimer’s disease.

The dataset now includes over one million patients in the company’s Real-World Data Cloud, a patient data network used to advance research, including clinical trial recruitment, uncovering prescriber trends, and modeling health economics and clinical outcomes. Beyond standard claims data, the dataset also includes deeper insights from more than 17,000 patients via enriched clinical notes from its national network of specialists treating Alzheimer’s patients.

It’s estimated that every 67 seconds, someone in the United States is diagnosed with Alzheimer’s disease. As a progressive and degenerative brain disorder, the disease can advance over time to drastically impact memory and other essential mental functions, ultimately having a potentially destructive effect on a person’s physical, social, and financial health.

Until now, trends in the medical history of Alzheimer’s patients have gone unnoticed, leaving opportunities for early intervention on the table. Access to this new dataset with its breadth of health information and deep understanding of the patient journeys, allows clinicians and researchers interested in Alzheimer’s disease to track at-risk patients for earlier intervention.

“We know that the pathogenesis of Alzheimer’s can begin decades before clinical symptoms emerge. And, while exciting, the new disease-modifying therapies entering the market for the first time only have a modest impact on a person’s disease journey if they are already in advanced cognitive decline," said Carl Marci, MD, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. "This, combined with the fact there is no cure, makes early detection and intervention to boost neuro-resiliency in patients even more crucial.”

To learn more about OM1’s Mental Health & Neuroscience Real-World Data Network, which includes robust datasets focused on Parkinson’s Disease, Major Depressive Disorder, Multiple Sclerosis, Bipolar Disorder I, and Schizophrenia, please email [e-mail].

About OM1

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWD/RWE. They have written the handbook on building clinical registries and developing the outcomes measure framework. OM1’s unprecedented innovation takes RWE from bench to practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research.